Morgans have today released a positive statement about FTT even though it is still undervaluing our SP.
However, they are at least talking in a positive sense and are maintaining the ADD recommendation and at a SP of 9.3cents.
Factor TherapeuticsA mid–November read out approaches
ADD (no change)Current price: A$0.073Target price: A$0.093Previous target: A$0.073Up/downside: 26.8%Reuters: FTT.AXBloomberg: FTT AUMarket cap: US$43.28mA$60.91mAverage daily turnover: US$0.05mA$0.07mCurrent shares o/s 834.0mFree float: 100.0%